The FDA granted a new indication for daratumumab (Darzalex, Janssen) for use with two standard-of-care regimens to treat patients with multiple myeloma (MM) who have received at least one prior therapy.
NOVEMBER 22, 2016
NOVEMBER 22, 2016
The FDA granted a new indication for daratumumab (Darzalex, Janssen) for use with two standard-of-care regimens to treat patients with multiple myeloma (MM) who have received at least one prior therapy.